X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (283) 283
humans (254) 254
pharmacology & pharmacy (183) 183
male (163) 163
adult (126) 126
cytochrome p-450 cyp2c19 (114) 114
female (110) 110
hydroxylation (94) 94
cytochrome p-450 enzyme system - metabolism (93) 93
omeprazole - analogs & derivatives (82) 82
pharmacokinetics (76) 76
aryl hydrocarbon hydroxylases (75) 75
mephenytoin - analogs & derivatives (73) 73
phenotype (73) 73
mephenytoin - metabolism (71) 71
mixed function oxygenases - metabolism (71) 71
middle aged (69) 69
2-pyridinylmethylsulfinylbenzimidazoles (68) 68
s-mephenytoin (67) 67
genotype (63) 63
mephenytoin (61) 61
omeprazole (59) 59
metabolism (57) 57
mixed function oxygenases - genetics (57) 57
cytochrome p-450 enzyme system - genetics (54) 54
cyp2c19 (50) 50
stereoisomerism (48) 48
drug interactions (46) 46
animals (44) 44
lansoprazole (44) 44
proton pump inhibitors (44) 44
chromatography, high pressure liquid (43) 43
polymorphism, genetic (42) 42
aged (41) 41
polymorphism (40) 40
omeprazole - pharmacokinetics (39) 39
s-mephenytoin 4'-hydroxylation (39) 39
abridged index medicus (38) 38
aryl hydrocarbon hydroxylases - genetics (38) 38
genetic-polymorphism (38) 38
area under curve (37) 37
aryl hydrocarbon hydroxylases - metabolism (33) 33
cytochrome p-450 enzyme inhibitors (33) 33
kinetics (33) 33
administration, oral (32) 32
cytochrome p-450 (31) 31
microsomes, liver - metabolism (31) 31
mephenytoin - urine (30) 30
microsomes, liver - enzymology (30) 30
enzyme inhibitors - pharmacology (29) 29
human liver-microsomes (29) 29
rabeprazole (29) 29
anti-ulcer agents - pharmacokinetics (27) 27
drug-metabolism (27) 27
mephenytoin - pharmacology (27) 27
toxicology (27) 27
omeprazole - blood (26) 26
rats (26) 26
adolescent (25) 25
in-vitro (25) 25
pharmacogenetics (25) 25
biotransformation (24) 24
cytochrome p-450 cyp3a (24) 24
human-liver-microsomes (24) 24
omeprazole - metabolism (24) 24
omeprazole - pharmacology (24) 24
debrisoquine (23) 23
proton pump inhibitor (23) 23
cross-over studies (21) 21
enzyme inhibitors - pharmacokinetics (21) 21
hydantoins - metabolism (21) 21
in vitro techniques (21) 21
microsomes, liver - drug effects (21) 21
oxidation (21) 21
pharmacology/toxicology (21) 21
liver - enzymology (20) 20
metabolites (20) 20
biochemistry & molecular biology (19) 19
debrisoquin - metabolism (19) 19
dose-response relationship, drug (19) 19
benzimidazoles - pharmacokinetics (18) 18
mixed function oxygenases - antagonists & inhibitors (18) 18
poor metabolizers (18) 18
population (18) 18
gastroenterology & hepatology (17) 17
plasma (17) 17
substrate specificity (17) 17
anticonvulsants - metabolism (16) 16
benzimidazoles - pharmacology (16) 16
enzymes (16) 16
helicobacter-pylori infection (16) 16
identification (16) 16
mephenytoin - pharmacokinetics (16) 16
cytochrome p450 (15) 15
disposition (15) 15
half-life (15) 15
isoenzymes - metabolism (15) 15
liver - drug effects (15) 15
oxidation-reduction (15) 15
alleles (14) 14
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drug Metabolism and Disposition, ISSN 0090-9556, 01/2010, Volume 38, Issue 1, pp. 92 - 99
The aim of the current study is to identify the human cytochrome P450 (P450) isoforms involved in the two oxidative steps in the bioactivation of clopidogrel... 
MECHANISM-BASED INHIBITION | ANTIAGGREGATING ACTIVITY | POLYMORPHISMS | TICLOPIDINE | PHARMACOKINETICS | HEALTHY-SUBJECTS | PHARMACOLOGY & PHARMACY | PRASUGREL | PHARMACODYNAMICS | MONOCLONAL-ANTIBODIES | ATORVASTATIN | Microsomes - metabolism | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Cytochrome P-450 Enzyme System - metabolism | Sulfaphenazole - pharmacology | Microsomes - drug effects | Cytochrome P-450 CYP3A - genetics | Cytochrome P-450 CYP1A2 - genetics | Antibodies - immunology | Omeprazole - pharmacology | Microsomes, Liver - enzymology | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Oxidoreductases, N-Demethylating - metabolism | Aryl Hydrocarbon Hydroxylases - immunology | Oxidation-Reduction | Enzyme Inhibitors - pharmacology | Ticlopidine - analogs & derivatives | Oxidoreductases, N-Demethylating - immunology | Cytochrome P-450 CYP3A - metabolism | Cell Line, Tumor | Cytochrome P-450 Enzyme System - genetics | Theophylline - pharmacology | Kinetics | Cytochrome P-450 CYP2C9 | Theophylline - analogs & derivatives | Oxidoreductases, N-Demethylating - genetics | Glutathione - metabolism | Ketoconazole - pharmacology | Biotransformation - physiology | Cytochrome P-450 CYP1A2 Inhibitors | Microsomes, Liver - drug effects | Ticlopidine - metabolism | NADP - metabolism | Platelet Aggregation Inhibitors - metabolism | Cytochrome P-450 CYP3A - immunology | Cell Line | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Cytochrome P-450 CYP1A2 - immunology | Biocatalysis | Mephenytoin - analogs & derivatives | Cytochrome P-450 CYP1A2 - metabolism | Aryl Hydrocarbon Hydroxylases - metabolism | Mephenytoin - pharmacology | Antibodies - pharmacology | Cytochrome P-450 CYP3A Inhibitors | Cytochrome P-450 CYP2C19 | Clopidogrel | Cytochrome P-450 CYP2B6 | Index Medicus
Journal Article
Journal Article
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 12/2008, Volume 36, Issue 12, pp. 2513 - 2522
Journal Article
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 12/2003, Volume 307, Issue 3, pp. 906 - 922
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 09/2006, Volume 80, Issue 3, pp. 235 - 245
Background: The liver plays a significant role in drug metabolism; thus it would be expected that liver disease may have a detrimental effect on the activity... 
COCKTAIL APPROACH | HUMAN PLASMA | FUNCTION TESTS | ENZYMES | CIRRHOSIS | LIQUID-CHROMATOGRAPHIC DETERMINATION | CHRONIC HEPATITIS-C | CAFFEINE | PHARMACOLOGY & PHARMACY | DRUG-METABOLISM | BREATH TEST | Mephenytoin - pharmacokinetics | Muscle Relaxants, Central - administration & dosage | Caffeine - administration & dosage | Chlorzoxazone - metabolism | Cytochrome P-450 Enzyme Inhibitors | Humans | Mephenytoin - metabolism | Middle Aged | Antihypertensive Agents - administration & dosage | Cytochrome P-450 Enzyme System - metabolism | Anticonvulsants - administration & dosage | Male | Antihypertensive Agents - metabolism | Mephenytoin - urine | Debrisoquin - pharmacokinetics | Caffeine - pharmacokinetics | Case-Control Studies | Chlorzoxazone - pharmacokinetics | Debrisoquin - administration & dosage | Debrisoquin - metabolism | Isoenzymes - metabolism | Adult | Chlorzoxazone - administration & dosage | Caffeine - metabolism | Severity of Illness Index | Anticonvulsants - pharmacokinetics | Phosphodiesterase Inhibitors - pharmacokinetics | Administration, Oral | Mephenytoin - analogs & derivatives | Anticonvulsants - metabolism | Antihypertensive Agents - pharmacokinetics | Muscle Relaxants, Central - metabolism | Theophylline - metabolism | Muscle Relaxants, Central - pharmacokinetics | Phosphodiesterase Inhibitors - administration & dosage | Phosphodiesterase Inhibitors - metabolism | Liver Diseases - physiopathology | Mephenytoin - administration & dosage | Liver Diseases - metabolism | Isoenzymes - antagonists & inhibitors | Physiological aspects | Medical colleges | Liver diseases | Pharmacy | Cytochrome P-450 | Index Medicus | Abridged Index Medicus
Journal Article
Bulletin of Experimental Biology and Medicine, ISSN 0007-4888, 11/2016, Volume 162, Issue 1, pp. 170 - 174
We developed a cytochrome P450 substrate—inhibitor panel for preclinical in vitro evaluation of drugs in a 3D histotypical microfluidic cell model of human... 
Biomedicine, general | Pathology | biotransformation | Biomedicine | HepaRG | preclinical in vitro studies | liver-on-a-chip | Internal Medicine | liver cell model | Laboratory Medicine | Cell Biology | Liver-on-achip | Liver cell model | Biotransformation | Preclinical in vitro studies | MEDICINE, RESEARCH & EXPERIMENTAL | RAT | P4502C9 | MOUSE | MONKEY | IN-VITRO | POTENT | DOG | DRUG-METABOLISM | Bupropion - metabolism | Phencyclidine - pharmacology | Cytochrome P-450 CYP2B6 - analysis | Omeprazole - metabolism | Cytochrome P-450 CYP2C19 - analysis | Liver - enzymology | Cytochrome P-450 CYP2C9 - analysis | Humans | Phencyclidine - analogs & derivatives | Substrate Specificity | Cytochrome P-450 CYP3A - analysis | Chromatography, High Pressure Liquid | Cytochrome P-450 CYP2B6 - metabolism | Ketoconazole - pharmacology | Sulfaphenazole - pharmacology | Testosterone - metabolism | Liver - drug effects | Microsomes, Liver - drug effects | Mass Spectrometry | Microsomes, Liver - enzymology | Cytochrome P-450 CYP2C9 - metabolism | Tolbutamide - metabolism | Mephenytoin - analogs & derivatives | Lab-On-A-Chip Devices | Mephenytoin - pharmacology | Cytochrome P-450 Enzyme Inhibitors - pharmacology | Cytochrome P-450 CYP3A - metabolism | Cytochrome P-450 CYP2C19 - metabolism | Metabolites | Liver | Microfluidics | Cytochrome P-450 | Cytochrome | Animal models | Ketoconazole | Cytochrome P450 | Tolbutamide | Mass spectroscopy | Metabolism | High-performance liquid chromatography | Drug development | Omeprazole | Testosterone | Bupropion | Hepatocytes | Isoforms | Drug metabolism | Sulfaphenazole | Propane | Index Medicus
Journal Article
Journal of Neurosurgery, ISSN 0022-3085, 06/2016, Volume 124, Issue 6, pp. 1746 - 1751
OBJECTIVE Symptomatic intracranial atherosclerotic disease (ICAD) has a high risk of recurrent stroke. Genetic polymorphisms in CYP2C19 and CES1 are associated... 
Antiplatelet | Stroke | Transient ischemic attack | Intracranial stenosis | Intracranial atherosclerotic disease | Vascular disorders | Pharmacogenomics | SURGERY | ARTERIAL-STENOSIS | GENOTYPE | RISK | transient ischemic attack | antiplatelet | stroke | vascular disorders | CLINICAL NEUROLOGY | intracranial atherosclerotic disease | TRIAL | S-MEPHENYTOIN | pharmacogenomics | MEPHENYTOIN METABOLISM | intracranial stenosis | OUTCOMES | CLINICAL-SIGNIFICANCE | Myocardial Infarction - genetics | Myocardial Infarction - epidemiology | Prospective Studies | Ticlopidine - therapeutic use | Ischemic Attack, Transient - genetics | Humans | Male | Genotyping Techniques | Stroke - genetics | Female | Stroke - epidemiology | Aspirin - therapeutic use | Carboxylic Ester Hydrolases - genetics | Platelet Aggregation Inhibitors - therapeutic use | Intracranial Arteriosclerosis - drug therapy | Ischemic Attack, Transient - drug therapy | Gene Frequency | Intracranial Arteriosclerosis - genetics | Kaplan-Meier Estimate | Cytochrome P-450 CYP2C19 - genetics | Stroke - drug therapy | Ticlopidine - analogs & derivatives | Ischemic Attack, Transient - epidemiology | Myocardial Infarction - drug therapy | Intracranial Arteriosclerosis - epidemiology | Heterozygote | Aged | Polymorphism, Single Nucleotide | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Pharmacogenomics Journal, ISSN 1470-269X, 08/2016, Volume 16, Issue 4, pp. 375 - 387
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 02/2016, Volume 81, Issue 2, pp. 327 - 340
Journal Article